# Acute Coronary Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/acute-coronary-syndrome

> 2 upcoming FDA catalysts in acute Coronary Syndrome: Leqvio (inclisiran sodium, NVS) on Feb to May 2027 (topline data readout); Leqvio (inclisiran sodium, NVS) on February 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 6, 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Acute Coronary Syndrome | completed | "NCT05754957 (A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-06 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05754957)) |
| Feb to May 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Acute Coronary Syndrome | scheduled | "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102628)) |
| February 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Acute Coronary Syndrome | scheduled | "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102628)) |

## Drugs

- [Milvexian](https://sec-api.dev/pdufa/milvexian) (JNJ)
- [Leqvio (inclisiran sodium)](https://sec-api.dev/pdufa/inclisiran) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/acute-coronary-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Acute Coronary Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/acute-coronary-syndrome

```bibtex
@misc{secapidev_indications_acute_coronary_syndrome_20261116,
  title        = {Acute Coronary Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/acute-coronary-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_acute_coronary_syndrome_20261116","title":"Acute Coronary Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/acute-coronary-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
